Regentis Biomaterials Ltd. (RGNT) Income Statement
RGNT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRGNT revenue and net income
RGNT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | −1,024.8% | — | — | — |
| Net income | −384.3% | — | — | — |
| EPS (diluted) | −383.9% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RGNT income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $331,000 | $1.6M | $806,000 | $971,000 |
| Sales, general & admin | $8.3M | $712,000 | $1.1M | $436,000 |
| Total operating expenses | $8.6M | −$932,000 | $1.9M | $1.4M |
| Operating income | −$8.6M | $932,000 | −$1.9M | −$1.4M |
| Interest expense | $324,000 | $171,000 | $173,000 | $0 |
| Income before taxes | −$13.6M | $4.8M | −$4.1M | −$1.4M |
| Net income | −$13.6M | $4.8M | −$4.1M | −$1.4M |
| EBITDA | −$13.3M | $5.0M | −$4.0M | −$1.4M |
| EPS (diluted) | −$2.64 | $0.93 | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RGNT's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RGNT financial results
Regentis Biomaterials reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $13.6 million. Diluted earnings per share came to −$2.64.
See the RGNT stock overview for the latest quote and news, or the RGNT chart for price history and technical indicators.
RGNT income statement FAQ
Does Regentis Biomaterials have revenue?
Regentis Biomaterials reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Regentis Biomaterials profitable?
No. Regentis Biomaterials reported a net loss of $13.6 million in fiscal 2025.
How much does Regentis Biomaterials spend on research and development?
Regentis Biomaterials spent $0.3 million on research and development in fiscal 2025.
What are Regentis Biomaterials's earnings per share?
Regentis Biomaterials earned $-2.64 per diluted share in fiscal 2025, compared with $0.93 a year earlier.
When does Regentis Biomaterials's fiscal year end?
Regentis Biomaterials's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.